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Objective: We evaluated the effect of long-term anticoagulant treatment (enoxaparin vs coumarin) in patients with deep
venous thrombosis (DVT) as to incidence of post-thrombotic syndrome (PTS) and recurrent venous thromboembolism.
We also analyzed the impact of thrombus regression after the anticoagulant treatment for these two outcomes.
Methods: A prospective study was designed in which 165 patients with symptomatic, unilateral, first-episode DVT were
randomized to a long-term anticoagulant treatment with coumarin or enoxaparin during at least 3 months. The rate of
thrombus regression was defined as the difference in Marder score after 3 months of treatment by venography. Follow-up
was performed at 3, 6, and 12 months, and yearly thereafter for 5 years. Venous disease was related to pathologic severity
of PTS according to the validated scale of Villalta as rated by a physician blinded to treatment. Recurrence of symptomatic
venous thromboembolism was documented objectively.
Results: The 5-year follow-up period was completed for 100 patients (enoxaparin, 56; coumarin, 44). A lesser incidence
of PTS was observed in the enoxaparin group (39.3% absent, 19.6% severe) than in the coumarin group (29.5% absent,
29.5% severe), although this difference was not statistically significant. The accumulated recurrence rate was 19.3% with
enoxaparin compared with 36.6% with coumarin (P  .02). Although the mean Marder score was significantly improved
in both groups (49.1% for enoxaparin vs 24.0% for coumarin; P  .016), a lower reduction in thrombus size was
associated with higher clinical events of recurrence (hazard ratio  1.97; 95% CI, 1.06-3.66; P  .032). A significant
inverse correlation was also found between the degree of thrombus regression at 3 months and the incidence at 5 years
of PTS (P  .007).
Conclusions: Residual venous thrombosis is an important risk factor for recurrent thromboembolism and PTS. A greater
reduction in thrombus size was associated with lesser clinical events of recurrence and consequently a lesser rate of PTS.
However, despite a greater recanalization with enoxaparin, the incidence of PTS was similar between both treatment
groups, probably because of the small sample size. Further investigations are needed to clarify the implication of the
anticoagulant treatment in the severity of PTS. ( J Vasc Surg 2008;48:953-9.)Post-thrombotic syndrome (PTS) is one the most seri-
ous long-term complications of deep venous thrombosis
(DVT) in the lower limb. The fundamental pathophysio-
logic disturbance found in these patients is sustained ve-
nous hypertension, which results from valvular incompe-
tence, outflow obstruction, calf muscle dysfunction, or a
combination of these. At present, development of PTS is
generally unpredictable, with the real incidence unknown
because of increases with the passage of the time.1-4
Former studies of the natural history of acute DVT
have reported that thrombus evolution is a dynamic pro-
cess, with recanalization and further thrombotic events
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thrombus regression appears to be correlated with clinical
recurrence, and recurrent venous thromboembolism
(VTE) is one of the most consistent risk factors associated
with the severity of post-thrombotic sequelae.6-9
Some years ago we published that enoxaparin, a low-
molecular-weight heparin, not only could be used safely
and effectively to treat DVT long-term, but it also was more
effective than coumarin, an oral anticoagulant, in reopen-
ing thrombosed veins.10 This venographic observation has
been corroborated in other studies, which concluded that
treatment with a low-molecular-weight heparin increased
the frequency of thrombus regression.11
Today, a thrombus reduction of at least 30% or more is
used in several trials as a sign of clinical benefit for the
individual patient.12 Because of this criterion, the purpose
of this study was to evaluate the effect of long-term antico-
agulant treatment of patients with DVT treated with enox-
aparin versus coumarin in the incidence of PTS, with the
expectation that a major recanalization might also result in
a reduced incidence of PTS after 5 years of follow-up.
Second, we determined the accumulated recurrence rate of
symptomatic VTE during the observational period, be-
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opment of PTS.
PATIENTS AND METHODS
Study design. A prospective cohort study was de-
signed in which 165 patients with symptomatic, unilateral,
and first-episode DVT were previously randomized to a
long-term (at least 3 months) anticoagulant treatment with
coumarin (international normalized ratio [INR], 2-3) or
enoxaparin once daily in fixed doses (4000 anti-Xa units, 40
mg) and then followed up for 5 years.
The primary end point was the incidence of PTS,
defined according to the validated scale of Villalta13 by a
physician blinded to treatment. Second, we assessed the
development of symptomatic recurrent VTE documented
objectively by serial perfusion lung scans or computed
tomography angiography (CT-angio) scans for pulmonary
embolism, and duplex scans or venograms for venous
thrombosis. Finally, we evaluated the impact of thrombus
regression, defined as the difference in Marder score after 3
months of treatment by venography, for these two out-
comes.
Informed written or verbal consent was obtained from
all patients in the study. The study protocol was approved
by our hospital’s institutional review board and ethical
committee.
Patients. All patients enrolled in the present study
were consecutive patients with symptomatic, unilateral, and
first-episode DVT confirmed by venography; they were
randomized by means of a prescribed schedule to long-
term treatment with oral anticoagulant therapy (coumarin:
INR, 2-3) or low-molecular-weight heparin (twice daily
enoxaparin 40 mg for 1 week followed by once-daily enox-
aparin 40 mg in fixed doses) for 3 months. The patients’
clinical characteristics and the criteria of inclusion and
exclusion were previously reported.10 No patients under-
went anticoagulant therapy after 3 months of treatment
unless they had a symptomatic recurrent thromboembo-
lism during the follow-up. At this time, all patients were
instructed and motivated to wear graduated compression
stocking (providing 40 mm Hg in the ankle) daily during
diurnal activities for at least 2 years.
Venographic assessment. A quantitative venographic
score (Marder score) was used to assess the extent of venous
thrombosis, with 0 points indicating noDVT and 40 points
indicating total occlusion of all deep veins.14 Control phle-
bographies were performed routinely in all patients after 3
months of treatment. The degree of thrombus regression at
3months was determined venographically by the difference
between the baseline and final Marder score after treat-
ment, and expressed as the percentage of reduction in the
score. According to this difference, each patient was as-
signed to one of two groups (30% decrease in score points
or30% decrease in score points), because this cutoff point
has been used in previous studies and thus has been valida-
ted.12,15 The assessment of venograms was scored by two
physicians who were blinded to treatment allocation and tothe sequence in which the tests were done (before or after
treatment).
Recurrent symptomatic VTE. Venograms, perfusion
lung scanning, and chest radiography were performed for
all patients at baseline. Recurrent DVT was reported if the
patients had new clinical signs of DVT and if the signs could
be confirmed independently by ultrasound scanning at the
vascular laboratory during follow-up as a new thrombus
with phlebography (first year) or as no compressibility of a
previous normalized venous segment. Patients with clini-
cally suspected pulmonary embolism underwent another
perfusion lung scan and chest radiography or angio-CT
scan to confirm the diagnosis. The diagnosis of recurrent
symptomatic VTE was established by an objective test and
confirmed by two independent physicians blinded to the
study to exclude bias. The DVT or pulmonary embolism
that occurred within the initial anticoagulation period (3
months) was considered in the analysis.
Criteria for PTS. After 5 years of follow-up, the ve-
nous disease was related to pathologic severity of PTS
according to the Villalta validated scale by a vascular physi-
cian who was unaware of previous clinical details of the
patient (M.M.P.). The Villalta’s scoring system13 assesses
five symptoms (pain, cramps, heaviness, pruritus, and par-
esthesia), and six signs (pretibial edema, induration of the
skin, hyperpigmentation, new venous ectasia, redness, and
pain during calf compression). For each item, the investi-
gators assigned a score of 0 (not present or minimal) to 3
(severe). A total score of 15 or more or the presence of a
venous ulcer indicated severe PTS; a total score of 5 to 14
indicated mild PTS; and total score less than 5 indicated
absent PTS.
Surveillance and follow-up. After discharge, all pa-
tients were seen in our vascular clinic every month during
the first trimester and then at 6 and 12 months, and yearly
during the 5-year observational period. A duplex ultra-
sound scan of both legs was performed every year in our
vascular laboratory by a certificated vascular physician. The
patients were instructed to come to the hospital immedi-
ately if symptoms or signs of recurrent DVT, pulmonary
embolism, or bleeding developed. Adherence to the study
was monitored by reviews of the patients’ charts. Patients
who failed to attend follow-up visits were contacted by
telephone, and cause of death for those who died was
documented by death certificates obtained from relatives or
the Registry of National Bureau of Statistics in Spain.
Statistical analysis. Descriptive statistics are reported
as n (%) or mean  SD unless stated otherwise. Univariate
analysis was performed to test the potential predictors of
PTS and recurrence. Kaplan-Meier estimates and 95% con-
fidence intervals (CIs) were calculated to assess the risk for
recurrent VTE in an intention-to-treat analysis. Time-
dependent Cox proportional hazards models were used to
calculate hazard ratios (HRs) for recurrent VTE in patients
with PTS (absent, mild, and severe), for patients with
Marder score  30% versus Marder score  30%, and for
patients treated initially with enoxaparin or coumarin. Pa-
tients who did not have recurrence were censored at the
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 4 González-Fajardo et al 955end of the available follow-up or at death. To assess the
statistical correlation between theMarder score and the risk
for PTS, we used the nonparametric Spearman test. All
analyses were performed with SPSS statistical software ver-
sion 14vs (SPSS Inc, Chicago, IL).
RESULTS
Study population. Of the 165 patients initially in-
cluded in the study, the 100 (60.6%) who completed the
5-year follow-up period constituted our study group: 56
patients treated with enoxaparin and 44 patients treated
with coumarin (Fig 1). Baseline clinical characteristics for
these 100 patients are shown in Table I.
Twenty-eight (17%) patients died; 17 (20%) were
treated with enoxaparin and 11 (13.8%) with coumarin
(P .28). One fatal pulmonary embolism was registered in
the group with enoxaparin at the beginning of treatment
(fifth day), and two pulmonary embolisms occurred during
follow-up in the group treated with coumarin. The other
causes of death included cancer (17 patients), cardiovascu-
lar disease (6 patients), stroke (1 patient), and crash (1
patient).
Thirty-seven (22.4%) patients were lost after the second
year of follow-up; 12 (14.1%) were treated with enoxaparin
and 25 (31.3%) with coumarin (P  .008).
Thrombus regression. A second venogram was per-
formed in all patients. No significant difference in Marder
score was observed between the two treatment groups at
baseline (Table I). After 3 months of treatment, the mean
Marder score was significantly decreased, although the
effect of therapy was significantly better after enoxaparin
treatment (49.1% 51.2% reduction inMarder score) than
after coumarin treatment (24.0%  51.0% reduction in
Marder score, P .016). Indeed, a thrombus regression
30%was observed in only 15 (26.78%) patients treated with
enoxaparin versus 24 (54.55%) patients treated with cou-
marin (P  .007).
Recurrent VTE. During the observational period of 5
After 5-years of Follow-up
165 Patients
(85 Enoxaparin/ 80 Coumarin)
100 Patients evaluable for PTS
(56 Enoxaparin/ 44Coumarin)
28 Deaths
(17 Enoxaparin/ 11 Coumarin)
37 Lost to Follow-up
(12 Enoxaparin/ 25 Coumarin)
12 Recurrent VTE/ 11 Patients 
(7 events Enoxaparin vs 5 events 
Coumarin)
5 Recurrent VTE/ 5 Patients
(0 events Enoxaparin vs 5 events 
Coumarin)
33 Recurrent VTE/ 27 Patients 
(13 events Enoxaparin vs 20 events 
Coumarin)
Fig 1. Flowchart of patients in the study for recurrent venous
thromboembolism and post-thrombotic syndrome.years, 50 episodes of symptomatic recurrent VTE werediagnosed in 43 (26.06%) patients. The intensity of oral
anticoagulation was 15% with INR  2.0, 64% with INR
from 2.0 to 3.0, and 21% with INR  3.0. Recurrences
were thromboses involving a previously affected extremity
in 33 (66%) cases and the contralateral leg in 7 (14%) case;
the remaining 10 (20%) cases had pulmonary embolisms.
The pulmonary embolisms were fatal in 3 (6%) cases. Seven
patients had two or more documented recurrent VTEs.
The cumulative incidence of recurrent VTE for the whole
series was 21.8% at 12 months, 23.7% at 24 months, 24.6%
at 36 months, 24.6% at 48 months, and 27.3% at 5 years.
The cumulative incidence of recurrence at 5 years was
19.3% with enoxaparin and 36.6% with coumarin (P .02;
Fig 2). On the basis of the Cox proportional hazards
model, the HR for recurrent VTE was 1.97 (95% CI,
1.06-3.66; P  .032) in patients treated with coumarin
compared with patients treated with enoxaparin.
Among the evaluated potential risk factors, the pres-
ence of residual venous thrombosis increased the risk for
recurrent VTE. The cumulative incidence of recurrence at
5 years was 40.5% in patients with a Marder score  30%
compared with 17.8% in patients with a Marder score 
30% after treatment (P  .001; Fig 3). Using a time-
dependent Cox proportional hazards model, we found that
a patient with thrombus regression  30% had a 62%
decrease in the risk for developing a recurrent VTE com-
pared with a patient with a thrombus regression  30%
(HR  0.38; 95% CI, 0.20-0.70; P  .002). In the
univariate analysis, patients with cancer had a higher risk
for recurrent events (P  .03), whereas those with a
trauma, surgery, or immobilization as risk factors of
DVT had a lower risk for recurrence (P  .03). Other
factors analyzed were not related with recurrence (Ap-
pendix I, online only).
Post-thrombotic syndrome. Despite regular use of
compression stockings (75.0%), a total of 65 (65%) patients
developed signs and symptoms of PTS. The PTS was con-
sidered moderate in 41 patients and severe in 24. Thirty-
five patients were asymptomatic after 5 years. A lesser
incidence of PTS was observed in the enoxaparin group
(39.3% absent, 19.6% severe) than in the coumarin group
(29.5% absent, 29.5% severe), although this difference was
not statistically significant (P  .43). Recurrent VTE and
lower thrombus regression after anticoagulant treatment
strongly predicted PTS. At 5 years, the cumulative inci-
dence of recurrence was 5.7% among patients without PTS,
31.7% in patients with mild PTS, and 50% in patients with
severe PTS (P  .001). Patients with mild PTS showed a
6-fold higher risk for recurrence compared with patients
without PTS (HR 6.19; 95% CI, 1.39-27.49; P .016).
This risk for recurrence was 11-fold in patients with severe
PTS compared with patients without PTS (HR  11.25;
95% CI, 2.5-50.35; P  .002; Fig 4). In contrast, patients
without PTS showed a mean Marder reduction of 52.38%
44.38% compared with 36.63%  50.16% in patients with
moderate manifestations, and only 19.62%  62.18 % in
patients with severe signs and symptoms of PTS (P .018;
Fig 5). A significant inverse correlation was found be-
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and the incidence of PTS at 5 years (P  .007). In our
patient cohort, an elevated weight was also an important
risk factor of PTS. Other factors analyzed in the univar-
iate analysis were not related with the PTS (Appendix II,
Table I. Patients’ demographic and clinical characteristics
All patients (n  10
Age (y) 57.4  14.4
Male gender 50 (50.0%)
Weight (kg) 74.4  11.4
Elastic stocking 75 (75.0%)
Risk factors for DVT
Trauma, surgery, or immobilization 26 (26.0%)
Cancer (paraneoplasia) 5 (5.0%)
Thrombophilia 9 (9.0%)
Unknown (idiopathic) 40 (40.0%)
Location of thrombus
Calf with popliteal vein 9 (9.0%)
Popliteal and femoral vein 57 (57.0%)
Popliteal, femoral, and iliac vein 24 (24.0%)
Iliac vein 10 (10.0%)
Marder score
Before treatment 21.7  11.2
After 3-month treatment 13.8  10.9
% Thrombus reduction 38.1  52.4
Recurrent thromboembolism
Recurrence of DVT (events)
Ipsilateral 23 (23.0%)
Contralateral 6 (6.0%)
Pulmonary embolism (events) 4 (4.0%)
Total (patients) 27 (27.0%)
Post-thrombotic syndrome
Absent 35 (35.0%)
Moderate 41 (41.0%)
Severe 24 (24.0%)
Values given as n (%) or mean  SD, as applied.
Fig 2. Kaplan-Meier estimates of the risk of recurrent venous
thromboembolism according to the treatment with enoxaparin or
coumarin (P  .02). The probability of recurrence was greater
among patients treated with coumarin than among patients treated
with enoxaparin (HR  1.97; 95% CI, 1.06-3.66; P  .032).online only).DISCUSSION
The short-term outcome of the initial anticoagulant ther-
apy for patients with acute DVT has been studied extensively,
and it has been demonstrated that low-molecular-weight hep-
Enoxaparin (n  56) Coumarin (n  44) P
59.8  13.3 54.3  15.2 .058
25 (44.6%) 25 (56.8%) .227
72.7  11.9 76.7  10.5 .082
41 (73.2%) 34 (77.3%) .642
19 (33.9%) 7 (15.9%) .041
2 (3.6%) 3 (6.8%) .652
2 (3.6%) 7 (15.9%) .032
21 (37.5%) 21 (43.2%) .565
5 (8.9%) 4 (9.1%) .609
35 (61.4%) 22 (50.0%)
11 (19.6%) 13 (29.5%)
5 (8.9%) 5 (11.4%)
20.2  11.6 23.6  10.4 .077
11.1  10.6 17.3  10.5 .004
49.1  51.2 24.0  51.0 .016
9 (16.1%) 14 (31.8%) .063
3 (5.4%) 3 (6.8%) 1.000
1 (1.8%) 3 (6.8%) .317
10 (17.9%) 17 (38.6%) .020
22 (39.3%) 13 (29.5%) .433
23 (41.1%) 18 (40.9%)
11 (19.6%) 13 (29.5%)
6050403020100
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32.9%
(47)
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(81)
35.7%
(45)
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(26)
14.9%
(59)
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(26)
14.9%
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(25)
17.8%
(55)
Marder reduction ≥ 30%
Marder reduction < 30%
Log-rank P= .001
(HR 0.38; CI95%, 0.20- 0.70; P= .002)
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Fig 3. Kaplan-Meier estimates of the risk of recurrent venous
thromboembolism according to the degree of thrombus regression
(P  .001). The probability of recurrence was greater among
patients with Marder score  30% than among patients with
Marder score  30% (HR  0.38; 95% CI, 0.20-0.70; P  .002).0)arin treatment is at least as effective and safe for initial treat-
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term clinical courses of the anticoagulant treatment and its
impact on PTS have been less well investigated. This series
is a prospective cohort study that offers the opportunity to
analyze PTS in a large number of well-defined patients with
a first episode of DVT. Predefined criteria were strictly
applied to the diagnosis of recurrent VTE, and a validated
scale was used to assess PTS. In addition, the venographic
assessment of the change in thrombus size over time per-
mitted objective evaluation of treatment effects in every
patient with two venograms.
This study demonstrated a significant inverse correla-
tion between the venographic effects of thrombus regres-
sion and the risk for PTS. Indeed, patients without PTS
showed a mean Marder reduction of 52.38% compared
6050403020100
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24.4%
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41.7%
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29.3%
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29.3%
(29)
45.8%
(13)
29.3%
(29)
50.0%
(12)
31,7%
(28)
Severe PTS
Mild PTS
Absent PTS
(HR 11.25; CI95%, 2.51- 50.35, P= .002)
(HR 6.19; CI 95%, 1.39- 27.49, P= .016)
Log-ramk P= .001
Kaplan-Meier one minus survival estimates (months)
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Fig 4. Kaplan-Meier estimates of the risk of recurrent venous
thromboembolism according to the presence of post-thrombotic
syndrome (PTS) (P  .001). The probability of recurrence was
greater among patients with moderate and severe PTS than among
patients without PTS (HR 6.19; 95% CI, 1.39-27.49; P .016;
vs HR  11.25; 95% CI, 2.51-50.35; P  .002).
Thrombus regression: mean and 95CI by SPT category
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Fig 5. Percentage of Marder reduction according to post-
thrombotic syndrome (PTS) category (P  .018).with a 36.63% thrombus reduction in patients with mod-erate manifestations, and only a 19.6% reduction in patients
with severe signs and symptoms of PTS (P  .018). This
finding means that patients with lower thrombus reduction
after anticoagulant treatment have a greater risk for PTS
sequelae during ensuing years. The clinical end point of
symptomatic recurrent VTE was also significantly corre-
lated with the venographics results. A residual venous
thrombosis conferred an increased likelihood of recurrence.
The cumulative incidence of recurrence at 5 years was
40.5% in patients with a Marder score 30% and 17.8% in
patients with a Marder score  30% after treatment (P 
.001). Our results, therefore, support the hypothesis that
residual venous thrombosis in patients with previous DVT
is a predictive risk factor for recurrent VTE6,17,18 and PTS.
With regard to treatment, long-term therapy with
enoxaparin was significantly more effective than coumarin
in reducing the size of the thrombus (49.1% reduction vs
24.0% reduction; P  .016), as well as the cumulative
recurrence rate of VTE (19.3% vs 36.6%; P .024). In fact,
patients treated with coumarin had a two-fold increase in
the risk for developing recurrent VTE compared with pa-
tients treated with enoxaparin (HR  1.97; 95% CI, 1.06-
3.66; P  .032). However, these findings were not associ-
ated with a significant lesser rate of PTS.
The incidence of PTS at 5 years was similar in both
groups of patients, although the most favorable tendency
was seen in those treated with enoxaparin (39.3% absent
and 19.6% severe) than in those treated with coumarin
(29.5% absent and 29.5% severe). The small sample size of
patients followed in each group, however, probably indi-
cates that this study did not have the statistical power to
show this difference. Thus, further investigations are
needed to clarify the implication of the anticoagulant treat-
ment in the incidence of PTS.
Post-thrombotic syndrome occurred in 65% of the
patients of our series. Data concerning risk factors for
developing PTS are contradictory.1,2,4,7,9,17 Although we
had expected that the extent of the initial DVT and its
location would be related to the risk for developing PTS,
we could not show such a relation, probably because all the
patients with distal DVT in our study had popliteal vein
involvement. In our patient cohort, only weight was linked
with an increased risk for PTS. Other factors analyzed were
not significant with regard to risk for PTS. Comparison of
data about PTS is hampered by a lack of standardized
diagnostic criteria and different observation times. We did
not use the CEAP classification system, because the clinical
stage assigned using this method is arbitrary and subjective
(Table II). Moreover, the discriminatory power is limited
compared with Villalta’s scoring system because of the
difficulty in establishing exactly what constitutes moderate
or severe PTS. In fact, this consideration varies in the
literature, that is, C4 sometimes is referred as mild PTS and
other times as severe PTS.4,6,19 In contrast, Villalta’s scor-
ing system combines good discriminatory power with a
reasonable relation to the ambulatory venous pressure.19
This score, based on subjective complaints and objective
clinical signs, has been shown to have good reproducibility
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ference with daily life.6,20
On the other hand, we found that a high risk for
recurrent VTE persists after anticoagulant treatment; this
risk resulted in a cumulative 27.3% incidence of this com-
plication after 5 years of follow-up, which is consistent with
other studies.7,9,16,21 However, the recurrent rate in the
coumarin group was quite high, mainly during the first
year. The effect of duration (only 3months) and the quality
of the anticoagulation could influence the overall rate of
recurrence, particularly in patients with continued risk for
recurrence. In accordance with previous studies,7,9,16,21
patients with cancer had a higher risk for recurrent events,
and patients with transient risk factors for DVT (trauma,
surgery, or immobilization) had a lower risk for recurrent
events. Other factors analyzed were not related with recur-
rence.
Residual thrombosis probably reflects an underlying
hypercoagulable state or a reduced thrombolytic capacity
that puts patients at higher risk for recurrent events. The
impaired venous flow, resulting in blood stasis and clot
formation, could increase venous hypertension and the risk
for valve incompetence.6 These pathophysiologic mecha-
nisms could justify the interrelation between PTS and
venous recurrence. Indeed, at 5 years the cumulative inci-
dence of recurrence was 5.7% among patients without PTS,
31.7% in patients with mild PTS, and 50% in patients with
severe PTS (P  .001). The presence of moderate PTS
conferred a 6-fold increased risk for recurrence, and this
rate was 11-fold when the patient showed severe PTS.
Because recurrent VTE strongly predicted development of
PTS, prevention of recurrence might be the key to decreas-
ing the incidence of this condition. Our findings correlate
with recent data suggesting that an elevated D-dimer at the
end of treatment is predictive of recurrence, and this out-
come could reflect insufficient anticoagulation despite ap-
parently adequate antithrombotic treatment.22,23 It seems
logical that the intensity and prolongation of anticoagula-
tion could be considered in selected patients, depending on
the presence of thrombus. Several studies have recently
investigated this fact.6,17,24,25 They showed that the ab-
sence of normalization in a Doppler ultrasound scan after
the first episode of DVT appears to be a factor that pro-
Table II. CEAP classification
CEAP Enoxaparin (n  56) Coumarin (n  44) P  .05
Class 0 5 (8.9%) 2 (4.5%) NS
Class 1 1 (1.8%) 1 (2.3%) NS
Class 2 7 (12.5%) 7 (15.9%) NS
Class 3 10 (17.9%) 9 (20.5%) NS
Class 4 24 (42.9%) 18 (40.9%) NS
Class 5 7 (12.5%) 6 (13.6%) NS
Class 6 2 (3.6%) 1 (2.3%) NS
NS, Not significant.
Values given as n (%).motes recurrence. A higher recurrence rate among patientswith limited thrombus regression, therefore, could justify a
prolonged prophylactic therapy.6,8,17,22,24
This study has several limitations. The small sample size
probably did not have sufficient statistical power with re-
gard to the incidence of PTS between both groups of
treatment. Indeed, at least 286 patients would be needed to
show a statistical difference for the incidence of absent PTS.
There was a significant loss to follow-up, despite our con-
tacting by telephone patients who did not attend follow-up
visits and documenting the cause of death (from death
certificates) for patients who died during the study. Finally,
the doses of enoxaparin used may have been insufficient; an
adjusted dose per kilogram of body weight would have
been more appropriate.
From a clinical practice standpoint, it would be of great
clinical importance if we could more effectively identify
patients with the highest risk for PTS. According to our
results, thrombus size evolution is an important predictor
of morbidity, in particular patients with poor recanalization
after long-term anticoagulant treatment show a greater risk
for recurrent VTE and PTS during ensuing years. It does
appear that, compared with coumarin, the rapid recanaliza-
tion with enoxaparin after DVT is associated with less
incidence of recurrence and minimizes PTS morbidity,
although additional research is needed to recommend
enoxaparin for long-term therapy. Otherwise, the use of
venographic score ensures an objective evaluation about
evolution of the thrombus and the efficacy of a treatment in
patients with DVT; however, venography is an invasive
technique that is used infrequently today. For this reason,
repeated noninvasive Doppler ultrasound scanning, despite
its limitations, could be an alternative method that might
help to stratify the risk for recurrence and development of
PTS during follow-up.
AUTHOR CONTRIBUTIONS
Conception and design: JAGF
Analysis and interpretation: JAGF, JC, ST, CVP
Data collection: MMP
Writing the article: JAGF
Critical revision of the article: MMP, CVP
Final approval of the article: JAGF, MMP, JC, ST, CVP
Statistical analysis: JC, ST
Overall responsibility: JAGF
REFERENCES
1. Rutherford RB. Pathogenesis and pathophysiology of the post-thrombotic
syndrome: clinical implications. Sem Vasc Surg 1996;9:21-5.
2. O=Shaughnessy AM, FitzGerald DE. Underlying factors influencing the
development of post-thrombotic limb. J Vasc Surg 2001;34:247-53.
3. Haenen JH, Janssen MCH, Wollersheim H, Van’t Hof MA, de Rooij
MJ, Van Langen H, et al. The development of postthrombotic syn-
drome in relationship to venous reflux and calf muscle pump dysfunc-
tion at 2 years after the onset of deep venous thrombosis. J Vasc Surg
2002;35:1184-9.
4. Asbeutah AM, Riha AZ, Cameron JD, McGrath BP. Five year outcome
study of deep vein thrombosis in the lower limbs. J Vasc Surg 2004;40:
1184-9.
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 4 González-Fajardo et al 9595. Meissner Mh, Caps MT, Bergelin RO, Manzo RA, Strandness DE.
Propagation, rethrombosis and new thrombus formation after acute
deep venous thrombosis. J Vasc Surg 1995;22:558-67.
6. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella
P, et al. Residual venous thrombosis as a predictive factor of recurrent
venous thromboembolism. Ann Intern Med 2002;137:955-60.
7. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al.
The long-term clinical course of acute deep venous thrombosis. Ann
Intern Med 1996;125:1-7.
8. Palareti G, Cosmi B. Predicting the risk of recurrence of venous throm-
boembolism. Curr Opin Hematol 2004;11:192-7.
9. Stain M, Schönauer V, Minar E, Bialonczykc C, Hirschl M, Weltermann
A, et al. The post-thrombotic syndrome: risk factors and impact on the
course of thrombotic disease. J Thromb Haemost 2005;3:2671-6.
1 0 . González-Fajardo JA, Arreba E, Castrodeza J, Pérez JL, Fernández L,
Agúndez I, et al. Venographic comparison of subcutaneous low-molecular
weight heparin with oral anticogulant therapy in the long-term treatment
of deep venous trombosis. J Vasc Surg 1999;30:283-92.
11. Gómez-Outes A, Lecumberri R, Lafuente-Guijosa A, Martínez-
González J, Carrasco P, Rocha E. Correlation between thrombus
regression and recurrent venous thromboembolism. Examining veno-
graphic and clinical effects of low-molecular-weight heparins: a meta-
analysis. J Thromb Haemost 2004;2:1581-7.
12. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV, and the Cortes
Investigators. Effects of a low-molecular-weight heparin on thrombus
regression and recurrent thromboembolism in patients with deep-vein
thrombosis. N Engl J Med 2001;344:626-31.
13. Villalta s, Bagatella P, Piccioli A, Lensing AW, Prins MH, Prandoni P.
Assessment of validity and reproducibility of a clinical scale for the PTS.
Haemostasis 1994;24:158A.
14. Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S,
Kim JR, et al. Quantitative venographic assessment of deep vein throm-
bosis in the evaluation of streptokinase and heparin therapy. J Lab Clin
Med 1977;89:1018-29.
15. Breddin HK. Treatment of deep vein thrombosis: is thrombosis regres-
sion a desirable endpoints? Sem Thromb Haemost 1997;23:179-83.
16. Holmström M, Aberg W, Lockner D, Paul C. Long term clinical
follow-up in 256 patients with deep-venous thrombosis initially treatedwith either unfractioned heparin or dalteparin: a retrospective analysis.
Thromb Haemost 1999;82:1222-6.
17. Galli M, Ageno W, Squizzato A, Dentali F, Manfredi E, Steidl L, et al.
Residual venous obstruction in patients with a single episode of deep
vein thrombosis and in patients with recurrent deep vein thrombosis.
Thromb Haemost 2005;94:93-5.
18. Young L, Ockelford P, Milne D, Rolfe-Vyson V, McKelvie S, Harper P.
Post-treatment residual thrombosis increases the risk of recurrent deep
vein thrombosis and mortality. J Thromb Haemost 2006;4:1919-24.
19. Kolbach DN, Neumann HA, Prins MH. Definition of the post-
trombotic syndrome, differences between existing classifications. Eur J
Vasc Endovasc Surg 2005;30:404-14.
20. Kahn SR, Hirsch A, Shrier I. Effect of PTS on health-related quality of
life after DVT. Arch Intern Med 2002;162:1144-8.
21. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembo-
lism after deep vein thrombosis: incidence and risk factors. Arch Intern
Med 2000;160:769-74.
22. Cosmi B, Legnani C, Cini M, Guazzaloza G, Palareti G. D-dimer level
in combination with residual venous obstruction and the risk of recur-
rence after anticoagulation withdrawal for a first idiopathic deep vein
thrombosis. Thromb Haemost 2005;94:969-74.
23. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al.
D-dimer testing to determine the duration of anticoagulation therapy.
N Engl J Med 2006;355:1780-9.
24. Piovella F, Crippa L, Barone M, Viganò D’Angelo S, Serafini S, Galli L,
et al. Normalization rates of compression ultrasonography in patients
with a first episode of deep vein thrombosis of the lower limbs: associ-
ation with recurrence and new thrombosis. Haematologica 2002;87:
515-22.
25. Siragusa S. Plasma D-dimer test accuracy can be affected by heparin
administration. Arch Intern Med 2003;163:246.
Received Mar 15, 2008; accepted May 12, 2008.
Additional material for this article may be found online
at www.jvascsurg.org.
PTS, Post-thrombotic syndrome.
Values given as n (%) or mean  SD, as applied.
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factors for recurrent venous thromboembolism
No
recurrence Recurrence P
Age (y) 59.6  13.2 59.8  14.7 .93
Gender .59
Male 66 (54.1%) 21 (48.8%)
Female 56 (45.9%) 22 (51.2%)
Weight (kg) 73.7  10.9 76.0  11.7 .35
Elastic stocking 59 (72.8%) 22 (81.5%) .37
Etiology
Trauma, surgery,
immobilization 54 (44.3%) 11 (25.6%) .03
Cancer 12 (9.8%) 10 (23.3%) .03
Thrombophilia 7 (5.7%) 4 (9.3%) .42
Unknown (idiopathic) 50 (41%) 18 (41.9%) .92
Location of thrombus .18
Calf with popliteal vein 14 (11.5% 6 (14.0%)
Popliteal and femoral vein 63 (51.6%) 14 (32.6%)
Popliteal, femoral, and
iliac vein 33 (27.0%) 16 (37.2%)
Iliac vein 12 (9.8%) 7 (16.3%)
% Marder score 46.1  29.9 11.1  63.8 .001
PTS .001
PTS Absent 33 (45.2%) 2 (7.4%)
PTS Moderate 28 (38.4%) 13 (48.1%)
PTS Severe 12 (16.4%) 12 (44.4%)
Treatment .029
Enoxaparin 69 (56.6%) 16 (37.2%)
Coumarin 53 (43.4%) 27 (62.8%)
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Absent PTS Moderate PTS Severe PTS P
Age (y) 55.7  15.9 57.6  13.5 59.4  13.4 .26
Gender .56
Male 19 (54.3%) 18 (43.9%) 13 (54.2%)
Female 16 (45.7%) 23 (56.1%) 11 (45.8%)
Weight (kg) 66.4  9.6 76.4  9.2 82.6  10.0 .000
Elastic stocking 25 (71.4%) 33 (80.5%) 17 (70.8%) .57
Etiology
Trauma, surgery, immobilization 16 (45.7%) 20 (48.8%) 10 (41.7%) .86
Cancer 1 (2.9%) 3 (7.3%) 1 (4.2%) .66
Thrombophilia 4 (11.4%) 1 (2.4%) 4 (16.7%) .13
Unknown (idiopathic) 15 (42.9%) 17 (41.5%) 8 (33.3%) .74
Location of thrombus .282
Calf with popliteal vein 1 (2.9%) 5 (12.2%) 3 (12.5%)
Popliteal and femoral vein 19 (54.3%) 26 (63.4%) 12 (50.0%)
Popliteal, femoral, and iliac vein 9 (25.7%) 7 (17.1%) 8 (33.3%)
Iliac vein 6 (17.1%) 3 (7.3%) 1 (4.2%)
% Marder score 52.37  44.37 36.63  50.16 19.61  62.17 .018
Recurrent VTE
DVT ipsilateral 1 (2.9%) 12 (29.3%) 10 (41.7%) .001
DVT contralateral 1 (2.9%) 1 (2.4%) 4 (16.7%) .041
PE 0 (0%) 3 (7.3%) 1 (4.2%) .268
Treatment .433
Enoxaparin 22 (62.9%) 23 (56.1%) 11 (45.8%)
Coumarin 13 (37.1%) 18 (43.9%) 13 (54.2%)VTE, Venous thromboembolism; DVT, deep venous thrombosis; PE, pulmonary embolism.
Values given as n (%) or mean  SD, as applied.
